Loading...
01/11 11:50
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals strong demand for high-value products, robust growth projections, and a resilient financial position despite FX headwinds and engineering delays. Management's optimistic guidance and strategic focus on capacity expansion and product innovation indicate positive sentiment. Although some uncertainties exist, particularly in the Engineering segment, the overall outlook supports a positive stock price movement.
Third quarter revenue Increased by 9% year-over-year to $303.2 million, driven by a 14% increase in the BDS segment and offset by a 19% decline in the Engineering segment. The growth was primarily due to strong performance in the BDS segment and favorable timing of product shipments.
Revenue from high-value solutions Grew 47% year-over-year, representing 49% of total company revenue. This growth was driven by strong demand for Nexa Syringes and the recovery in EZ-fill vials.
Consolidated gross profit margin Increased by 240 basis points to 29.2% in the third quarter of 2025. This was due to a favorable mix of high-value solutions, financial improvements at Latin and Fishers facilities, and recovery in vial demand. However, it was partially offset by lower gross profit from the Engineering segment and currency translation impacts.
Operating profit margin Increased to 17.4%, and on an adjusted basis, rose 220 basis points to 18.5%, driven predominantly by an increase in gross profit.
Net profit Totaled $36.1 million with diluted EPS of $0.13. On an adjusted basis, net profit was $38.5 million, and adjusted diluted EPS increased 17% to $0.14.
Adjusted EBITDA Increased to $77.8 million, with the adjusted EBITDA margin improving by 280 basis points to 25.7%.
BDS segment revenue Increased by 14% to $266.7 million, driven by a record level of high-value solutions and recovery in EZ-fill vials. On a constant currency basis, BDS revenue grew by 17%.
Engineering segment revenue Decreased by 19% to $36.4 million, driven by lower revenue from glass conversion and assembly lines. Gross profit margin for the segment declined to 10.4% due to lower revenue and a higher proportion of complex legacy projects.
Cash and cash equivalents Stood at $113.3 million as of September 30, 2025, with net debt of $333 million.
Capital expenditures Totaled $54.9 million for the third quarter of 2025. Net cash from operating activities increased to $47.2 million, and free cash flow was approximately EUR 260,000 for the quarter.
Nexa Syringes: Achieved 47% growth in high-value solutions, driven by Nexa syringes. Nexa platform is optimized for sensitive biologics and integrates seamlessly with auto-injectors.
EZ-fill Cartridges: Selected by a leading manufacturer for a GLP-1 biosimilar for type 2 diabetes, marking one of the first FDA-approved biosimilars in the U.S. Offers compatibility with pen injector systems, accelerating time to market.
Injectable Biologics: Strong demand for premium containment and delivery solutions for injectable biologics, driven by rising pharmaceutical innovation and self-administration trends.
U.S. Manufacturing Investments: Major pharmaceutical players are investing in U.S. manufacturing operations, driven by onshoring and regulatory upgrades.
Engineering Segment Optimization: Operational improvements made, but financial performance remains below expectations. Strengthening sales organization and refining commercial processes to improve order flow.
Fishers and Latina Facilities: Scaling commercial production for Nexa Syringes and EZ-fill cartridges. New clean room and injection molding machines being installed to support large device programs.
High-Value Solutions Focus: Strategic shift towards high-value solutions, now representing 49% of total revenue. Transitioning away from low-value syringes and diagnostics.
Sustainability Commitment: Awarded EcoVadis silver medal, placing in the top 15% globally for sustainability performance.
Foreign Currency and Tariff Costs: The company faced headwinds from foreign currency and certain tariff costs that were not mitigated, which tempered margins in the third quarter.
Engineering Segment Performance: The Engineering segment's financial performance is below expectations, with a 19% revenue decline and negative operating profit margin due to lower revenue from glass conversion and assembly lines, and a higher proportion of complex legacy projects.
Order Conversion in Engineering Segment: Converting the pipeline of new opportunities into orders has been slower than anticipated, impacting the segment's recovery and profitability.
Currency Translation Impact: Currency translation was worse than anticipated, with an expected impact of $15 million to $16 million for the full year, higher than the prior range of $12 million to $15 million.
Margin Dilution at New Facilities: The Fishers and Latina facilities are currently margin dilutive, though expected to improve as they scale up operations.
Pending Customer Validations: Customer validations for new vial lines and contract manufacturing activities are expected to begin in mid-2026, delaying revenue realization.
Regulatory and Quality Standards: Customers are upgrading technology to meet higher quality standards and stringent regulations, such as Annex 1, which may require additional investments and adjustments.
Revenue Guidance for Fiscal 2025: The company reiterates its fiscal 2025 revenue guidance in the range of $1.16 billion to $1.19 billion.
Adjusted EBITDA Guidance for Fiscal 2025: Adjusted EBITDA is expected to range between $288.5 million and $301.8 million.
Adjusted Diluted EPS Guidance for Fiscal 2025: Adjusted diluted EPS is projected to be between $0.50 and $0.54.
High-Value Solutions Revenue Contribution: The revenue from high-value solutions is now expected to range between 43% and 44% of total revenue, an increase from the prior assumption of 40% to 42%.
Currency Translation Impact: The impact from currency translation is now expected to be approximately $15 million to $16 million, compared to the prior range of $12 million to $15 million.
Capital Investment Projects: The company is advancing its capital investment projects in Fishers and Latina. Syringe lines in Fishers are in various stages of ramp-up, with vial lines expected to begin customer validations in mid-2026. Commercial activities for contract manufacturing are expected to begin at the end of 2026 or early 2027. In Latina, commercial production for Nexa Syringes is scaling and will continue into 2026, with preparations underway for the next phase of EZ-fill cartridge production.
Engineering Segment Outlook: The company expects to see benefits from strengthening the sales organization and refining commercial processes in the coming quarters. Long-term demand for manufacturing technologies remains strong, supported by industry capacity expansion and investments in U.S. manufacturing operations.
Market Trends and Tailwinds: The company anticipates strong secular tailwinds from the growth in biologics, rising pharmaceutical innovation, and the increasing trend towards self-administration of medicine. Customers are investing in new capital projects, onshoring operations in the U.S., and upgrading technology to meet higher quality standards and stringent regulations.
The selected topic was not discussed during the call.
The earnings call reveals strong demand for high-value products, robust growth projections, and a resilient financial position despite FX headwinds and engineering delays. Management's optimistic guidance and strategic focus on capacity expansion and product innovation indicate positive sentiment. Although some uncertainties exist, particularly in the Engineering segment, the overall outlook supports a positive stock price movement.
The earnings call reveals several concerns: lowered guidance for adjusted EBITDA and EPS, negative free cash flow expectations, and gross profit margin dilution due to new facilities. While there is some optimism for 2025 recovery and high-value solutions growth, the lack of a shareholder return plan and operational efficiency challenges weigh negatively. The Q&A section highlights management's unclear responses on vial sales and HVS revenue, adding uncertainty. These factors, combined with a decline in the Engineering segment, suggest a negative stock price movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
